Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Bundamedik TbkISX:BMHS +1.01%76 Debt-to-Equity is 0.63 as of Jun. 2026, which is 10% below its 10-year median of 0.70. GuruFocus rates ISX:BMHS with a GF Score™ of 76/100 and a GF Value™ of Rp278.84 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 565 Healthcare Providers & Services companies, PT Bundamedik Tbk ranks worse than 67.08% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PT Bundamedik Tbk's Debt-to-Equity or its related term are showing as below:
ISX:BMHS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.34 Med: 0.7 Max: 1.08
Current: 0.77
During the past 8 years, the highest Debt-to-Equity Ratio of PT Bundamedik Tbk was 1.08. The lowest was 0.34. And the median was 0.70.
ISX:BMHS's Debt-to-Equity is ranked worse than 67.08% of 565
companies
in the Healthcare Providers & Services industry
Industry Median: 0.43
vs ISX:BMHS: 0.77
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PT Bundamedik Tbk Debt-to-Equity Related Terms
PT Bundamedik Tbk Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:BMHS vs HCA, THC, EHC: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk (ISX:BMHS) has a Debt-to-Equity of 0.63 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PT Bundamedik Tbk and its competitors. This is 10% below median its historical median of 0.70. Over the past decade, PT Bundamedik Tbk's Debt-to-Equity has ranged from 0.34 to 1.08. According to the industry distribution chart, PT Bundamedik Tbk ranks #379 out of 565 companies in the Healthcare Providers & Services industry, placing it in the top 67.1%.
Is PT Bundamedik Tbk's Debt-to-Equity too high?
PT Bundamedik Tbk's current Debt-to-Equity of 0.63 is 10% below median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 1.08. The Healthcare Providers & Services industry median Debt-to-Equity is 0.43. PT Bundamedik Tbk's value of 0.63 is 46.5% above this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #379 out of 565 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PT Bundamedik Tbk has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's Debt-to-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #379 out of 565 companies for Debt-to-Equity. This places PT Bundamedik Tbk in the lower half of its industry. The industry median Debt-to-Equity is 0.43. PT Bundamedik Tbk's value of 0.63 is 46.5% above this benchmark. Historically, PT Bundamedik Tbk's own Debt-to-Equity has ranged from 0.34 to 1.08 over the past decade. While the company's 10-year median is 0.70 vs. the industry median of 0.43, PT Bundamedik Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.43, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current Debt-to-Equity of 0.63 is 46.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current Debt-to-Equity is 0.63, which is 10% below median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp278.84, compared to a current price of Rp200.00 — trading 28.3% below its estimated fair value. The current Debt-to-Equity is 0.63, which is 10% below median its 10-year median of 0.70 and 46.5% above the Healthcare Providers & Services industry median of 0.43. PT Bundamedik Tbk's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current Debt-to-Equity is 0.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp200.00 is trading 28.3% below its estimated GF Value™ of Rp278.84.
GuruFocus considers PT Bundamedik Tbk to be Modestly Undervalued.
Key valuation signals for ISX:BMHS:
Debt-to-Equity: 0.63 (10% below median its 10-year median of 0.70)
GF Value™: Rp278.84 vs. price of Rp200.00 (28.3% below fair value)
Industry Position: 46.5% above the Healthcare Providers & Services median (#379 of 565)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
76GF Score
Get the complete analysis for ISX:BMHS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
